"The Trump administration announced plans to crack down on pharmaceutical advertising on television and social media platforms that could disrupt billions of dollars in annual ad spending. President Donald Trump signed a presidential memorandum on Tuesday that calls on federal health agencies to require pharmaceutical companies to disclose more side effects in their ads and enforce existing rules about misleading ads."
"Drug companies spent $10.8 billion in 2024 on direct-to-consumer pharmaceutical advertising in total, according to a report from the advertising data firm MediaRadar. AbbVie Inc. and Pfizer Inc. were particularly big spenders. AbbVie alone spent $2 billion on direct-to-consumer drug ads last year, primarily on advertising for the company's anti-inflammatory drugs Skyrizi and Rinvoq. The medicines brought in more than $6.5 billion for AbbVie in the second quarter of 2025."
President Donald Trump signed a presidential memorandum directing federal health agencies to require more disclosure of side effects in pharmaceutical advertisements and to enforce existing rules against misleading claims. The measures target television and social media advertising and stop short of an outright ban. Health and Human Services Secretary Robert F. Kennedy Jr. has long prioritized limiting direct-to-consumer drug ads. Drug companies spent $10.8 billion on such advertising in 2024, with AbbVie and Pfizer major spenders. The FDA plans dozens of cease-and-desist actions and thousands of warning letters. Proponents say ads prompt medical conversations; critics note emphasis on costly brand-name drugs.
Read at Bloomberglaw
Unable to calculate read time
Collection
[
|
...
]